Adam A Blakstvedt

US Patent:

8067024, Nov 29, 2011

Filed:

Jan 25, 2007

Appl. No.:

11/627032

Inventors:

Adam Blakstvedt - Big Lake MN, US
Jesus Casas - Brooklyn Park MN, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61F 2/02
A61K 9/14

US Classification:

424423, 424489

Abstract:

Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain anti-inflammatory agents, are disclosed. The anti-inflammatory agents are selected from the group consisting of Sanglifehrin A, Sanglifehrin B, Sanglifehrin C, Sanglifehrin D, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the anti-inflammatory agent with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-anti-inflammatory agent blends are disclosed. Additionally, medical devices having a coating comprising at least one anti-inflammatory agent in combination with at least one additional therapeutic agent are also disclosed.

US Patent:

20060095020, May 4, 2006

Filed:

Oct 31, 2005

Appl. No.:

11/263098

Inventors:

Jesus Casas - Brooklyn Park MN, US
Laura Christoferson - Ramsey MN, US
Adam Blakstvedt - Big Lake MN, US

Assignee:

Medtronic, Inc. - Minneapolis MN

International Classification:

A61K 9/22

US Classification:

604890100

Abstract:

The disclosure is directed to apparatus and techniques that deliver an active agent, such as an antibiotic age nt or loosening agent to a patient by diffusion. An element of the medical device deployed proximate to the cells or host tissue includes a diffusible material, which comprises a lumen. An agent introduced into the lumen diffuses through the diffusible material to the cells or host tissue or tissues. The invention can be applied to medical devices that are placed partially inside a patient, as well as those that are fully implanted. Some embodiments support moving the internal element of a medical device proximate to targeted cells, such as a tumor, and administering an active agent to the targeted cells by diffusion. The disclosure also encompasses a testing system that helps test and develop apparatus and techniques for delivering an agent by diffusion.

US Patent:

20060095021, May 4, 2006

Filed:

Nov 2, 2004

Appl. No.:

10/979774

Inventors:

Laura Christoferson - Ramsey MN, US
Adam Blakstvedt - Big Lake MN, US

International Classification:

A61K 9/22

US Classification:

604892100, 604095030

Abstract:

The disclosure is directed to apparatus and techniques that deliver an antibiotic or loosening agent to a patient by diffusion. An element of the medical device deployed proximate to the living cells includes a diffusible material, which comprises a lumen. An agent introduced into the lumen diffuses through the diffusible material to the living cells or tissues. The invention can be applied to medical devices that are placed partially inside a patient, as well as those that are fully implanted. Some embodiments support moving the internal element of a medical device proximate to targeted cells, such as a tumor, and administering an antibiotic agent to the targeted cells by diffusion. The disclosure also encompasses a testing system that helps test and develop apparatus and techniques for delivering an agent by diffusion.

US Patent:

20060099235, May 11, 2006

Filed:

Nov 11, 2004

Appl. No.:

10/987021

Inventors:

Adam Blakstvedt - Big Lake MN, US
Jamie Williams - St. Louis Park MN, US
Molly Schiltgen - Lake Elmo MN, US

Assignee:

Medtronic Vascular, Inc. - Santa Rosa CA

International Classification:

A61K 48/00
A61F 13/00

US Classification:

424422000, 424093200

Abstract:

Medical devices and related methods for making and using same suitable for treating or inhibiting restenosis are proved. Specifically, compositions and methods for I kappa B alpha (IkBα)nuclear factor kβ (NFkβ) complex breakdown inhibition are provided. One embodiment includes a CRM-1 protein binding composition such as leptomycin B. Another embodiment includes a combination of a CRM-1 protein binding composition and a nucleic acid encoding for mammalian IkBα. Medical devices disclosed include catheters and vascular stents.

US Patent:

20080015546, Jan 17, 2008

Filed:

Jul 11, 2007

Appl. No.:

11/776149

Inventors:

Jesus Casas - Brooklyn Park MN, US
Adam Blakstvedt - Big Lake MN, US
Molly Schiltgen - Lake Elmo MN, US
Kent Wika - New Brighton MN, US

International Classification:

A61M 31/00

US Classification:

604522000, 604093010

Abstract:

The present invention relates to methods, kits, and compositions for safe and efficient delivery of a bioagent to a targeted area of an organ. The method comprises preparing a suspension comprising the bioagent, a contrast agent, and a vehicle, wherein said suspension has an osmolarity from about 270 mOsm to about 440 mOsm; and dispensing at least a portion of said suspension into the targeted area. The invention further provides a kit for delivering a bioagent into a targeted area of an organ comprising: a delivery device; a contrast agent; and a vehicle.

US Patent:

20090227952, Sep 10, 2009

Filed:

Mar 10, 2008

Appl. No.:

12/045120

Inventors:

Adam Blakstvedt - Big Lake MN, US
Jesus Casas - Brooklyn Park MN, US
Timothy Robinson - Savage MN, US

Assignee:

MEDTRONIC VASCULAR, INC. - Santa Rosa CA

International Classification:

A61M 5/00

US Classification:

604117

Abstract:

Methods, systems and devices for delivering a diagnostic or therapeutic treatment, substance or device to a target area located within the body of a human or animal subject. A tissue penetrating catheter is positioned within a body lumen near the target area. A hollow penetrator is then advanced from the tissue penetrating catheter and penetrated from the body lumen in which the penetrating catheter is positioned into tissue in the direction of the target area. Thereafter, an elongate optical device (e.g., an optically equipped guidewire or catheter) is advanced through the hollow penetrator and continues to advance through tissue, in the direction of the target area. The elongate optical device is connected to an optical processing device (e.g., a spectrometer) which provides optically determined data (e.g., spectral reflectance, pH, oxygen concentration, temperature) indicating when the elongate optical device has entered the target area. The elongate optical device is then used to facilitate delivery of a diagnostic or therapeutic modality, substance or device into the target area.